Replies to post #280009 on Avid Bioservices Inc (CDMO)

[Protector]

ku, no, the approval of a first 3rd line treatment for NSCLC DURING Sunrise blew it.

If the patients in the CTRL arm would have evented because after progression they didn't have any next treatment anymore then (and frankly for the patients I am happy they did have a next treatment available) then bavituximab would not only have proven again that it worked but Sunrise would not have stopped early. Nothing Garnick could do unless one wants to claim to know the outcome of Opdivo trials UP-FRONT of course.